<code id='090AF33541'></code><style id='090AF33541'></style>
    • <acronym id='090AF33541'></acronym>
      <center id='090AF33541'><center id='090AF33541'><tfoot id='090AF33541'></tfoot></center><abbr id='090AF33541'><dir id='090AF33541'><tfoot id='090AF33541'></tfoot><noframes id='090AF33541'>

    • <optgroup id='090AF33541'><strike id='090AF33541'><sup id='090AF33541'></sup></strike><code id='090AF33541'></code></optgroup>
        1. <b id='090AF33541'><label id='090AF33541'><select id='090AF33541'><dt id='090AF33541'><span id='090AF33541'></span></dt></select></label></b><u id='090AF33541'></u>
          <i id='090AF33541'><strike id='090AF33541'><tt id='090AF33541'><pre id='090AF33541'></pre></tt></strike></i>

          Home / fashion / entertainment

          entertainment


          entertainment

          author:entertainment    Page View:11
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In